JP2015511963A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015511963A5 JP2015511963A5 JP2015500593A JP2015500593A JP2015511963A5 JP 2015511963 A5 JP2015511963 A5 JP 2015511963A5 JP 2015500593 A JP2015500593 A JP 2015500593A JP 2015500593 A JP2015500593 A JP 2015500593A JP 2015511963 A5 JP2015511963 A5 JP 2015511963A5
- Authority
- JP
- Japan
- Prior art keywords
- breast cancer
- hormone receptor
- receptor positive
- triple negative
- dihydropyrazino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261611374P | 2012-03-15 | 2012-03-15 | |
| US61/611,374 | 2012-03-15 | ||
| US201261715331P | 2012-10-18 | 2012-10-18 | |
| US61/715,331 | 2012-10-18 | ||
| PCT/US2013/031185 WO2013138553A1 (en) | 2012-03-15 | 2013-03-14 | Treatment of cancer with tor kinase inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017218014A Division JP6470820B2 (ja) | 2012-03-15 | 2017-11-13 | Ｔｏｒキナーゼ阻害剤を用いた癌の治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015511963A JP2015511963A (ja) | 2015-04-23 |
| JP2015511963A5 true JP2015511963A5 (https=) | 2016-04-21 |
Family
ID=48014333
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015500593A Pending JP2015511963A (ja) | 2012-03-15 | 2013-03-14 | Ｔｏｒキナーゼ阻害剤を用いた癌の治療 |
| JP2017218014A Active JP6470820B2 (ja) | 2012-03-15 | 2017-11-13 | Ｔｏｒキナーゼ阻害剤を用いた癌の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017218014A Active JP6470820B2 (ja) | 2012-03-15 | 2017-11-13 | Ｔｏｒキナーゼ阻害剤を用いた癌の治療 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20130245027A1 (https=) |
| EP (1) | EP2825169B1 (https=) |
| JP (2) | JP2015511963A (https=) |
| KR (1) | KR102057359B1 (https=) |
| CN (1) | CN104271139A (https=) |
| AU (1) | AU2013202993B2 (https=) |
| BR (1) | BR112014022707A2 (https=) |
| CA (1) | CA2867348A1 (https=) |
| ES (1) | ES2678250T3 (https=) |
| IL (1) | IL234641B (https=) |
| MX (1) | MX360880B (https=) |
| MY (1) | MY178012A (https=) |
| NI (1) | NI201400112A (https=) |
| NZ (1) | NZ628407A (https=) |
| PH (1) | PH12014502046B1 (https=) |
| SG (1) | SG11201405724RA (https=) |
| TW (1) | TWI635862B (https=) |
| WO (1) | WO2013138553A1 (https=) |
| ZA (1) | ZA201406701B (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013203714B2 (en) | 2012-10-18 | 2015-12-03 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity |
| CA2909579A1 (en) | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Combination therapy comprising a tor kinase inhibitor and n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer |
| CN105377299B (zh) | 2013-04-17 | 2018-06-12 | 西格诺药品有限公司 | 用于治疗前列腺癌的包含二氢吡嗪并-吡嗪化合物和雄激素受体拮抗剂的组合疗法 |
| CA2908742C (en) * | 2013-04-17 | 2021-06-01 | Signal Pharmaceuticals, Llc | Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer |
| WO2014172436A1 (en) | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer |
| US9630966B2 (en) | 2013-04-17 | 2017-04-25 | Signal Pharmaceuticals, Llc | Treatment of cancer with dihydropyrazino-pyrazines |
| US9505764B2 (en) | 2013-04-17 | 2016-11-29 | Signal Pharmaceuticals, Llc | Treatment of cancer with dihydropyrazino-pyrazines |
| CA2909629C (en) | 2013-04-17 | 2022-12-13 | Signal Pharmaceuticals, Llc | Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one |
| NZ629486A (en) | 2013-05-29 | 2017-11-24 | Signal Pharm Llc | Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use |
| ES2823756T3 (es) | 2014-04-16 | 2021-05-10 | Signal Pharm Llc | Métodos para tratar el cáncer usando terapia de combinación de inhibidores de quinasa TOR |
| US9512129B2 (en) | 2014-04-16 | 2016-12-06 | Signal Pharmaceuticals, Llc | Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer |
| NZ714742A (en) | 2014-04-16 | 2017-04-28 | Signal Pharm Llc | Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use |
| WO2015160882A1 (en) | 2014-04-16 | 2015-10-22 | Signal Pharmaceuticals, Llc | SOLID FORMS COMPRISING 7-(6-(2-HYDROXYPROPAN-2YL) PYRIDIN-3-YL)-1-(TRANS)-4-METHOXYCYCLOHEXYL)-3, 4-DIHYDROPYRAZINO[2,3-b] PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF |
| TWI787284B (zh) | 2017-06-22 | 2022-12-21 | 美商西建公司 | 以b型肝炎病毒感染表徵之肝細胞癌之治療 |
| CN112933088B (zh) * | 2021-02-03 | 2022-02-22 | 南华大学附属第一医院 | Y041-5921在制备抗肿瘤药物中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2666624C (en) | 2006-10-19 | 2015-12-29 | Signal Pharmaceuticals, Llc | Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors |
| MX337906B (es) | 2006-10-19 | 2016-03-28 | Signal Pharm Llc | Compuestos de heteroarilo, composiciones de los mismos, y su uso como inhibidores de proteina cinasas. |
| AU2009234259A1 (en) * | 2008-04-11 | 2009-10-15 | Bionovo, Inc. | Anticancer methods employing extracts of Gleditsia sinensis Lam |
| US20110200556A1 (en) * | 2008-08-20 | 2011-08-18 | The United States Of America, As Represented By Th E Secretary, Department Of Health And Human Servi | Chemoprevention of head and neck squamous cell carcinomas |
| US8110578B2 (en) * | 2008-10-27 | 2012-02-07 | Signal Pharmaceuticals, Llc | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway |
| SG10201500511TA (en) | 2009-10-26 | 2015-03-30 | Signal Pharm Llc | Methods Of Synthesis And Purification Of Heteroaryl Compounds |
-
2013
- 2013-03-14 MY MYPI2014702602A patent/MY178012A/en unknown
- 2013-03-14 US US13/803,305 patent/US20130245027A1/en not_active Abandoned
- 2013-03-14 BR BR112014022707-1A patent/BR112014022707A2/pt not_active IP Right Cessation
- 2013-03-14 CN CN201380024241.3A patent/CN104271139A/zh active Pending
- 2013-03-14 KR KR1020147028898A patent/KR102057359B1/ko active Active
- 2013-03-14 JP JP2015500593A patent/JP2015511963A/ja active Pending
- 2013-03-14 AU AU2013202993A patent/AU2013202993B2/en not_active Ceased
- 2013-03-14 ES ES13713003.5T patent/ES2678250T3/es active Active
- 2013-03-14 CA CA2867348A patent/CA2867348A1/en not_active Abandoned
- 2013-03-14 EP EP13713003.5A patent/EP2825169B1/en active Active
- 2013-03-14 MX MX2014011118A patent/MX360880B/es active IP Right Grant
- 2013-03-14 SG SG11201405724RA patent/SG11201405724RA/en unknown
- 2013-03-14 WO PCT/US2013/031185 patent/WO2013138553A1/en not_active Ceased
- 2013-03-14 TW TW102109151A patent/TWI635862B/zh active
- 2013-03-14 NZ NZ628407A patent/NZ628407A/en not_active IP Right Cessation
-
2014
- 2014-09-12 ZA ZA2014/06701A patent/ZA201406701B/en unknown
- 2014-09-12 NI NI201400112A patent/NI201400112A/es unknown
- 2014-09-14 IL IL234641A patent/IL234641B/en active IP Right Grant
- 2014-09-15 PH PH12014502046A patent/PH12014502046B1/en unknown
-
2017
- 2017-11-13 JP JP2017218014A patent/JP6470820B2/ja active Active
-
2022
- 2022-10-28 US US17/976,471 patent/US20230338370A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015511963A5 (https=) | ||
| JP2015511964A5 (https=) | ||
| JP2015516375A5 (https=) | ||
| JP2015510891A5 (https=) | ||
| Costa et al. | Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review | |
| JP2021102637A5 (https=) | ||
| Wicki et al. | First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13) | |
| KR102456088B1 (ko) | 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체 | |
| EP2825170B1 (en) | Treatment of cancer with tor kinase inhibitors | |
| TWI708605B (zh) | 以ｔｏｒ激酶抑制劑治療癌症 | |
| AU2013203156B2 (en) | Treatment of cancer with TOR kinase inhibitors | |
| AU2013202992B2 (en) | Treatment of cancer with TOR kinase inhibitors | |
| EP2825169B1 (en) | Treatment of cancer with tor kinase inhibitors | |
| JP2016516816A5 (https=) | ||
| KR20230049620A (ko) | 교류 전기장에 대한 암세포 민감도를 증가시키기 위한 방법 및 조성물 | |
| Guidetti et al. | Phase II study of sorafenib in patients with relapsed or refractory lymphoma | |
| JP2015534981A5 (https=) | ||
| WO2014134240A1 (en) | Treatment of cancer with tor kinase inhibitors | |
| Konar et al. | Synthesis and clinical development of palbociclib: An overview | |
| Oberthür et al. | Simultaneous inhibition of IGF1R and EGFR enhances the efficacy of standard treatment for colorectal cancer by the impairment of DNA repair and the induction of cell death | |
| BR112015013196A2 (en) | combinations of a pi3k / akt inhibitor compound with a her3 / egfr inhibitor compound and methods of use | |
| Mortensen et al. | 337 The discovery and preclinical characterization of CC-223, a novel mTOR kinase inhibitor under clinical investigation | |
| Xu et al. | 338 CC-223, a Selective mTOR Kinase Inhibitor, Potently Inhibits Proliferation of a Large Panel of Cancer Cell Lines in Vitro | |
| AU2015213400B2 (en) | Treatment of cancer with TOR kinase inhibitors | |
| Narla et al. | 336 Antitumor Activity of mTOR Kinase Inhibitor CC-223 in a Mouse Model of Glioblastoma |